5-HT 4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles

British Journal of Pharmacology

Volumn 155, Issue 7, 2008, Pages 1005-1014

  Afzal, F ^a   Andressen, K W ^a   Mork H K ^a   Aronsen, J M ^a   Sjaastad, I ^a,b   Dahl, C P ^a,c   Skomedal, T ^a   Levy, F O ^a   Osnes, J B ^a   Qvigstad, E ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 HT; 5 HT 4 receptor; cAMP; Heart failure; Phosphodiesterase; Serotonin

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; CILOSTAMIDE; CYCLIC AMP; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; ROLIPRAM; SEROTONIN; SEROTONIN 4 RECEPTOR; SPLEEN EXONUCLEASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPLANT; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE MUSCLE; HEART PAPILLARY MUSCLE; HEART VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; HUMAN TISSUE; INOTROPISM; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOIMMUNOASSAY; RAT; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; REGULATORY MECHANISM; ANIMAL; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; DRUG EFFECT; HEART CONTRACTION; HEART FAILURE; HEART VENTRICLE; LIGATION; METABOLISM; MIDDLE AGED; WISTAR RAT;

ANIMALS; CORONARY VESSELS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HEART FAILURE; HEART VENTRICLES; HUMANS; LIGATION; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN, 5-HT4;

EID: 56749096601     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.339     Document Type: Article

References (47)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA et al. (2001). Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89: 997-1004.
3. i. Proc Natl Acad Sci USA 100: 940-945.
4. Beavo JA, Brunton LL (2002). Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 3: 710-718.
5. 4 receptor antagonist in heart failure. Br J Pharmacol 150: 143-152.
6. 4 receptors in failing rat ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol 293: H2367-H2376.
7. Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS et al. (2003). The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with β-arrestins. J Biol Chem 278: 49230-49238.
8. 4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol 43: 767-779.
9. 4 mRNA in heart failure. Naunyn-Schmiedeberg's Arch Pharmacol 370: 157-166.
10. Chandra M, Gupta V, Johri AK, Misra R, Kumar A, Gujrati V et al. (1994). Serotonergic mechanisms in heart failure. Indian Heart J 46: 153-156.
11. 1-adrenoceptors in human atrial myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 374: 249-253.
12. Cuffe MS, Califf RM, Adams Jr KF., Benza R, Bourge R, Colucci WS et al. (2002). Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287: 1541-1547.
13. 4 receptor-induced responses: fading of the response and influence of development. Br J Pharmacol 147: 140-157.
14. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA et al. (2005). Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111: 2469-2476.
15. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM et al. (2003). Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41: 997-1003.
16. Fischmeister R, Castro LR, bi-Gerges A, Rochais F, Jurevicius J, Leroy J et al. (2006). Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99: 816-828.
17. 1-adrenoceptors. Br J Pharmacol 153: 710-720.
18. Sα overexpression. Circ Res 78: 517-524.
19. Ca,L in frog ventricular myocytes. J Physiol 551: 239-252.
20. Kaumann AJ, Levy FO (2006a). 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111: 674-706.
21. 4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium. Br J Pharmacol 147: 128-130.
22. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD et al. (2005). Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123: 25-35.
23. Lohse MJ, Engelhardt S, Eschenhagen T (2003). What is the role of β-adrenergic signaling in heart failure? Circ Res 93: 896-906.
24. Lugnier C (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
25. Lugnier C, Keravis T, Le BA, Pauvert O, Proteau S, Rousseau E (1999). Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1472: 431-446.
26. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A et al. (2004). Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95: 67-75.
27. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR et al. (2006). Compartmentalized phosphodiesterase 2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98: 226-234.
28. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC (1991). Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 88: 15-19.
29. Okruhlicova L, Tribulova N, Eckly A, Lugnier C, Slezak J (1996). Cytochemical distribution of cyclic AMP-dependent 3′, 5′-nucleotide phosphodiesterase in the rat myocardium. Histochem J 28: 165-172.
30. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al. (1991). Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468-1475.
31. 4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc Res 65: 869-878.
32. 4 receptors induced in the acute failing heart. Circ Res 97: 268-276.
33. Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, Karpen JW (2001). A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc Natl Acad Sci USA 98: 13049-13054.
34. Robison GA, Butcher RW, Sutherland EW. (1971). Cyclic AMP and hormone action. In: Robison GA, Butcher RW, Sutherland EW (eds.) Cyclic AMP. Academic press: New York and London. pp 17-46.
35. Rochais F, bi-Gerges A, Horner K, Lefebvre F, Cooper DM, Conti M et al. (2006). A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res 98: 1081-1088.
36. Schumann HJ, Endo M, Wagner J (1974). Positive inotropic effects of phenylephrine in the isolated rabbit papillary muscle mediated both by α- and β-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 284: 133-148.
37. Shahid M, Nicholson CD (1990). Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn-Schmiedeberg's Arch Pharmacol 342: 698-705.
38. 1- vs β-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand 177: 449-458.
39. Sjaastad I, Sejersted OM, Ilebekk A, Bjørnerheim R (2000). Echocardiographic criteria for detection of postinfarction congestive heart failure in rats. J Appl Physiol 89: 1445-1454.
40. 1-adrenoceptor-mediated and β-adrenoceptor- mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 280: 721-729.
41. 3H-cAMP) ligand, or of unlabeled ligand only. Acta Pharmacol Toxicol (Copenh) 46: 200-204.
42. Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, Ding JZ et al. (1997). Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 96: 3116-3123.
43. Sole MJ, Shum A, van Loon GR (1979). Serotonin metabolism in the normal and failing hamster heart. Circ Res 45: 629-634.
44. Takahashi K, Osanai T, Nakano T, Wakui M, Okumura K (2002). Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure. Heart Vessels 16: 249-256.
45. Vargas ML, Hernandez J, Kaumann AJ (2006). Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br J Pharmacol 147: 158-163.
46. 2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci USA 102: 909-914.
47. Zaccolo M, Pozzan T (2002). Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Sci 295: 1711-1715.